Basic Information
| LncRNA/CircRNA Name | PART1 |
| Synonyms | NA |
| Region | GRCh38_5:60487713-60547657 |
| Ensemble | ENSG00000152931 |
| Refseq | NR_024617 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Gefitinib | |
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, RIP |
| Sample | blood, cell lines (TE1, TE6, TE8, TTn, KYSE-450) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA PART1 was upregulated in gefitinib-resistant cells when compared to parental ESCC cells. elevated PART1 promoted gefitinib resistance by competitively binding to miR-129 to facilitate Bcl-2 expression in ESCC cells. extracellular PART1 could be incorporated into exosomes and transmitted to sensitive cells, thus disseminating gefitinib resistance. exosomal PART1 may induce gefitinib resistance through inhibiting apoptotic proteins and cell apoptosis via Bcl-2/Bax pathway. |
| Pubmed ID | 30049286 |
| Year | 2018 |
| Title | Exosome-mediated Transfer of lncRNA PART1 Induces Gefitinib Resistance in Esophageal Squamous Cell Carcinoma via Functioning as a Competing Endogenous RNA. |
External Links
| Links for PART1 | GenBank HGNC NONCODE |
| Links for esophageal squamous cell carcinoma | OMIM COSMIC |